Anti-CD38 mAb Market to Accelerate Substantially During the Study Period 2020-2034 Owing to a Strong Uptake of DARZALEX in Multiple Myeloma and Expected Entry of anti-CD38 mAbs in Autoimmune Diseases | DelveInsight.

The article from Pharma Business Week discusses the Anti-CD38 mAb Market Insights report by DelveInsight, focusing on the expected growth of the market from 2020 to 2034. Currently, Johnson&Johnson's DARZALEX and Sanofi's SARCLISA are the only approved therapies for Multiple Myeloma. DARZALEX has shown exceptional effectiveness and safety, positioning it as the gold standard in therapy. Other emerging indications for anti-CD38 mAbs include Systemic Lupus Erythematosus, Chronic Kidney Disease, and IgA Nephropathy. Companies like Takeda Pharmaceuticals and Genmab are developing novel anti-CD38 mAbs for future market availability. [Extracted from the article]